โŒ

Normal view

There are new articles available, click to refresh the page.
Before yesterdayMain stream

$6 billion Commure was just ordered to stop selling a hot healthtech product in its latest legal challenge

13 May 2025 at 06:00
Athelas CEO Tanay Tandon
Athelas CEO Tanay Tandon, pictured, co-founded the remote patient monitoring startup with Deepika Bodapati.

Athelas

  • A court just ordered healthcare startup Commure to stop selling its hospital panic buttons.
  • Commure has been embroiled in a legal battle with the makers of the tech for more than a year.
  • The $6 billion startup now won't be able to market its Strongline Pro product or get new customers, according to a recent injunction.

$6 billion healthcare startup Commure has been ordered to stop making one of its most historically successful products in a legal face-off with the tech's creators.

Commure, the startup cofounded by General Catalyst CEO Hemant Taneja and incubated by the VC firm, has been embroiled in legal turmoil for over a year with the makers of its former workplace safety tech, Strongline.

Canopy Works created the technology behind Strongline, a wearable panic button for hospital staff that was once Commure's best-selling product. Canopy severed its ties with Commure in 2023, after which Commure released an "upgrade" to Strongline called Strongline Pro.

Canopy alleged in a lawsuit against Commure in the Northern District of California that Commure's Strongline Pro was a derivative of Canopy's Strongline, which violated the companies' contract. Now, a federal district court has sided with Canopy and ordered Commure to stop selling Strongline Pro.

The court's preliminary injunction, filed on April 25 in the Northern District of California and made public Friday afternoon, prohibits Commure from distributing or marketing Strongline Pro to new customers, at least while the underlying breach of contract case proceeds.

It's a big win for Canopy, which says it's lost business as hospital customers "upgrade" from Canopy's Strongline to Commure's Strongline Pro. Strongline's business was Commure's sole growing revenue source at the time of its $6 billion merger with fellow General Catalyst portfolio company Athelas, as Business Insider reported in September. It's unclear how much revenue Strongline Pro now contributes to Commure or how much that revenue could be affected by the court order.

"This injunction validates the years of dedicated R&D and significant investment Canopy has poured into its unique healthcare safety platform," A Canopy spokesperson said in a statement to BI. "This ruling provides certainty for our customers, confirming they are partnered with the creator of this technology and can trust the integrity and performance of the Canopy system safeguarding their employees."

Commure has asked the court to delay the injunction's enforcement. In a statement to BI, Commure SVP and General Manager Dan Warner said he expects the Ninth Circuit Court of Appeals to overturn the injunction, adding that "the law and facts are firmly on Commure's side," and that Commure developed Strongline Pro entirely in-house.

For its part, Commure has expanded well beyond its workplace safety product in the past year. The startup has signaled its intentions to dig deeper into healthcare AI following its acquisition of revenue cycle management company Athelas, buying ambient scribing company Augmedix in July 2024 for $139 million in cash, and scooping up another General Catalyst portfolio company, AI-powered care coordination platform Memora Health, in December.

General Catalyst is also closing a deal to buy Akron, Ohio-based health system Summa Health. The firm has said it plans to integrate healthcare technology into the hospitals' operations, an endeavor that would likely include Commure's tech.

Commure's battle with Canopy

Commure and Canopy created their first agreement to make Commure a reseller of Canopy's technology in 2019.

In 2022, Commure bought the rights to white-label and sell Strongline's wearable panic buttons for hospital staff. Canopy Works, then known as SMP Labs, remained a separate company and retained ownership of the intellectual property.

Tensions quickly escalated after the acquisition. In late 2022, Commure sued Canopy when the company tried to terminate its partnership with Commure. Canopy had cited delayed payments as a reason for breaking away from the startup.

That lawsuit was dismissed and later settled, but the damage was done. By December 2023, Canopy spun out for good as a new company to sell its safety technology directly to health systems.

Commure moved quickly to rebuild its workplace safety business, launching Strongline Pro just days after Canopy's debut. Commure positioned Strongline Pro as a successor to the original Strongline product, although filings with federal regulators showed substantial similarities between the two devices, per BI's September reporting.

Commure holds that "Strongline Pro was developed independently by Commure without using any information from Canopy," per the Friday injunction.

After Canopy's exodus, Commure filed a lawsuit against Canopy in April 2024, alleging that Commure had contributed to the development of Strongline's original concept and that Canopy had violated its contractual obligations to provide its tech to Commure through the end of the year. Commure also raised concerns about alleged security vulnerabilities in Canopy's technology.

As ordered in the injunction, existing Strongline Pro customers can continue to use Strongline Pro, but Commure cannot upgrade those systems or contract with new Strongline Pro customers.

In his statement to BI, Commure's Warner also referenced a prior civil decision in which he said a judge ruled that a Canopy employee, who previously worked at Commure, had misappropriated Commure's confidential information for Canopy's benefit. Warner said the ruling "confirms that Commure, not Canopy, is the party harmed in this dispute." BI could not independently review the filing as it has not been made public.

A Canopy spokesperson said in response that the arbitration was a separate issue with one of Commure's former employees that is "completely unrelated to the ongoing litigation with Canopy."

Read the original article on Business Insider

These 7 healthcare startups are primed to make acquisitions in 2025

28 February 2025 at 02:00
Abhinav Shashank wearing an Innovaccer hoodie.
Innovaccer CEO Abhinav Shashank.

Innovaccer.

  • Few large companies appear to have the appetite to make big acquisitions in healthcare this year.
  • Startups desperate to sell may find better luck with other digital health companies flush with cash.
  • Here are seven healthcare startups that look poised to make more deals in 2025.

Many healthcare startups and investors are hoping for a fresh wave of M&A in 2025 after a slow few years for company combinations โ€” and the right buyers might just be their startup peers.

At the end of 2024, many healthcare startups were quietly raising down rounds and looking around for buyers to extend their lifespans, Business Insider reported in November.

While some startups are desperate for deals, nearly a dozen investors and bankers told BI in February that few large companies had the appetite to make big acquisitions in healthcare this year.

"In digital health, it's not necessarily that it doesn't make sense to consolidate โ€” it's there's a lack of consolidators out there," said Aaron DeGagne, a senior healthcare analyst at PitchBook.

But those startups could find a new home with other digital health startups that are flush with cash. Several healthcare startups have been vocal about their M&A ambitions this year as they await dropping interest rates and are eager to jump on opportunities for inorganic growth.

These are seven healthcare startups that appear ready to make more acquisitions in 2025.

Caresyntax
Bjoern von Siemens.
Bjoern von Siemens, the founder and CEO of Caresyntax.

Caresyntax

Founded: 2013

Last fundraise: $180 million in Series C extension and growth debt expansion funding in August 2024.

The surgical software company Caresyntax is planning on using a fresh fundraise to power acquisitions.

Caresyntax, which combines information from surgical videos, medical records, and other sources to help make surgeries safer and more profitable, grabbed $180 million in August. In a release about the funding round, the company said it was looking to make several acquisitions in 2024 and beyond.

Josh Zeidman, Caresyntax's chief business officer, told BI the company was looking for acquisitions in areas such as surgical AI applications, video analytics, and data capture modules.

He said Caresyntax was primarily considering deals with venture-backed startups or other small private companies rather than with private equity or public companies.

Caresyntax said in its August release that it had acquired multiple surgical data and technology assets in 2023, though it didn't name those acquisitions. Zeidman told BI that Caresyntax's primary get in 2023 was acquiring the team behind health data consulting company CQInsights, including its CEO, Dr. Bruce Ramshaw, who became Caresyntax's chief medical informatics officer.

Commure
Tanay Tandon
Athelas CEO Tanay Tandon, pictured, cofounded the remote patient monitoring startup with Deepika Bodapati.

Athelas

Founded: 2017

Last fundraise: $70 million from General Catalyst, as part of Commure's $6 billion merger with Athelas in October 2023

M&A is a core part of the healthcare startup Commure's playbook.

Commure, the health software company cofounded by General Catalyst CEO Hemant Taneja, has made seven acquisitions to date. Former employees told BI in September that Commure's leadership regularly touted the slogan "M&A is in our DNA."

Most recently, the startup bought the care coordination platform Memora Health in December.

Memora Health was another General Catalyst investment, as was Athelas, the revenue cycle management company Commure merged with in 2023.

Commure also announced in July a $139 million all-cash acquisition of the public medical scribing company Augmedix.

Commure didn't respond to requests for comment for this story.

Datavant
Kyle Armbrester.
Datavant CEO Kyle Armbrester.

Datavant

Founded: 2017

Last fundraise: Sixth Street and other investors contributed an undisclosed amount of funding in 2021 to support Datavant's $7 billion merger with Ciox Health.

The health data startup Datavant is hunting for more deals after kicking off a fresh M&A push in the fall.

CEO Kyle Armbrester told BI in January that the company, which has made 11 acquisitions since 2017, planned to make at least "one or two" more acquisitions in early 2025.

Datavant manages patient data exchanges between providers, payers, and life sciences organizations. The private equity firm New Mountain Capital is Datavant's controlling shareholder.

Datavant most recently made two deals in September: It bought the data privacy organization Trace Data and two data analytics products from the healthcare AI startup Apixio.

Armbrester said Datavant was looking for companies building technology for healthcare providers and life sciences organizations, especially those with existing market traction.

"We're large and diversified, and I think we're in a really good space to take a smaller smarter and apply their logic or artificial intelligence or analytics across that vast network to see a lot of benefit," Armbrester said.

Flare Capital Partners' Parth Desai told BI in December that he expected private-equity-backed healthcare companies to make tuck-in acquisitions in 2025 as they prepare for potential IPOs in 2026.

Hinge Health
Daniel Perez.
Daniel Perez, the cofounder and CEO of Hinge Health.

Hinge Health

Founded: 2014

Last fundraise: $400 million in Series E funding in October 2021

2025 could be the year that Hinge Health finally goes public. Multiple investors and bankers told BI in February that the physical therapy startup was the best choice for the year's first digital health IPO, with margins more closely resembling a software company than a healthcare services provider.

Hinge Health hired banks including Morgan Stanley last year to prepare for a public market debut, hoping to go public in early 2025, BI reported in September.

Those ambitions shouldn't preclude the startup from making acquisitions. Similar to Datavant, Hinge Health could look to notch some deals before an IPO to further its growth.

CEO Daniel Perez told BI in October 2023 that Hinge Health was actively looking for smaller companies to acquire, a sentiment the startup echoed to Endpoints News at the start of 2024.

The company hasn't announced any acquisitions since then.

Hinge Health declined to comment for this story.

Innovaccer
Abhinav Shashank wearing an Innovaccer hoodie.
Innovaccer CEO Abhinav Shashank.

Innovaccer.

Founded: 2014

Last fundraise: $275 million in Series F funding in January 2025

Innovaccer is hoping to use a fresh mega-round to fuel acquisitions.

At the start of the year, the company announced its $275 million Series F round, a combination of primary and secondary investments from investors such as B Capital Group and Kaiser Permanente.

Less than two weeks later, Innovaccer announced it had bought the actuarial analytics startup Humbi AI.

Innovaccer also made two acquisitions last year, scooping up the healthcare marketing platform Cured in January 2024 and the pharmacy software company Pharmacy Quality Solutions that March.

The startup told Endpoints News this January that it was looking to buy more health tech companies this year. CEO Abhinav Shashank said Innovaccer was looking at companies working to enhance the patient experience, relieve administrative burdens for providers with automation, and decrease costs.

"Our acquisition strategy is to accelerate our roadmap by partnering with like-minded mission-driven companies that can help customers drive these transformations," Shashank said in a statement to BI.

Fabric
Headshot of Aniq Rahman.
Aniq Rahman, the founder and CEO of Fabric.

Fabric

Founded: 2021

Last fundraise: $60 million in Series A funding in February 2024

Fabric, the only early-stage startup on this list, has centered M&A in its approach since its March 2023 launch. The healthcare startup said it planned to accelerate that strategy further this year.

Fabric made four acquisitions in 15 months, most recently buying the physician practice group TeamHealth's virtual care business in September. Before that, Fabric bought the virtual care business MeMD from Walmart, the asynchronous virtual care platform Zipnosis from Bright Health, and the generative AI startup Gyant.

Fabric sells software to help emergency rooms manage patients, including by directing them to telehealth services where appropriate. General Catalyst led its $60 million Series A round in February 2024.

Fabric's founder and CEO, Aniq Rahman, told BI in September that Fabric was starting to look at bigger acquisition targets.

"A lot of the companies that are struggling to go raise capital right now, or some of these larger businesses that are reevaluating their position in the market, are creating opportunities for us as well," he said. "Pretty much every week, there's inbound coming in from investors that are like, we have assets in our portfolio that may be accretive to what you're doing with Fabric."

Rahman told BI in February that Fabric expected to ramp up its M&A strategy even more in 2025.

He said Fabric had "already met with a few dozen companies this year around M&A" and was watching opportunities across venture-backed startups, private-equity-owned companies, and even spinouts of public companies.

Transcarent
Glen Tullman.
Transcarent CEO Glen Tullman.

Transcarent

Founded: 2020

Last fundraise: $126 million in Series D funding in May 2024

Transcarent, the healthcare benefits navigation startup helmed by Glen Tullman, the former Livongo CEO, kicked off the year with a big acquisition.

The company announced in January that it would buy its fellow care navigation company Accolade from the public markets in a $621 million all-cash deal.

It's one of at least three deals Transcarent has made to date. The startup bought 98point6's virtual care tech and physician group in March 2023 and merged with the surgical care startup BridgeHealth in 2020.

Transcarent's top M&A priority for 2025 is to successfully integrate Accolade into its business, CEO Glen Tullman told BI in a statement.

Still, he said the company remained strategically opportunistic and was consistently evaluating opportunities for growth and innovation.

Transcarent is backed by General Catalyst, which certainly hasn't shied away from M&A for its healthcare bets, as seen through Fabric and Commure's rich histories of acquisitions. Tullman's own investment firm, 7wire Ventures, also an investor in Transcarent, has similarly combined its own portfolio companies, most recently selling the mental health startup Caraway to the pediatric care company Summer Health in February.

General Catalyst and 7wire Ventures co-led Transcarent's $126 million Series D round in May.

Read the original article on Business Insider

โŒ
โŒ